Home > Insider Trading > Filing (0001209191-20-038999)

Filing Details

Accession Number:: 0001209191-20-038999
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-25 19:09:51
Reporting Period:: 2020-06-23

Accepted Time:: 2020-06-25 19:09:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808158	Repare Therapeutics Inc.	RPTX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1745958	Davis Jerel	C/O Repare Therapeutics Inc. 7210 Frederick-Banting, Suite 100 St-Laurent A8		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2020-06-23	2,054,198	$0.00	2,705,660	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	156,335	$0.00	205,915	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	68,398	$0.00	90,090	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	61,791	$0.00	81,387	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	2,443,883	$0.00	2,443,883	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	111,361	$0.00	2,817,021	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	8,475	$0.00	214,390	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	3,708	$0.00	93,798	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	3,350	$0.00	84,737	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	875,568	$0.00	3,319,451	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	458,282	$0.00	458,282	No	4	C	Indirect	See Footnote
Common Shares	Acquisiton	2020-06-23	150,000	$20.00	608,282	No	4	P	Indirect	See Footnotes
Common Shares	Acquisiton	2020-06-23	100,000	$20.00	3,419,451	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Class A Preferred Shares	Disposition	2020-06-23	2,054,198	$0.00	2,054,198	$0.00
Common Shares	Class A Preferred Shares	Disposition	2020-06-23	156,335	$0.00	156,335	$0.00
Common Shares	Class A Preferred Shares	Disposition	2020-06-23	68,398	$0.00	68,398	$0.00
Common Shares	Class A Preferred Shares	Disposition	2020-06-23	61,791	$0.00	61,791	$0.00
Common Shares	Class A Preferred Shares	Disposition	2020-06-23	2,443,883	$0.00	2,443,883	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	111,361	$0.00	111,361	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	8,475	$0.00	8,475	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	3,708	$0.00	3,708	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	3,350	$0.00	3,350	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	875,568	$0.00	875,568	$0.00
Common Shares	Class B Preferred Shares	Disposition	2020-06-23	458,282	$0.00	458,282	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date.
The securities are held by Versant Venture Capital V, L.P. ("VVC V"). The Reporting Person is a managing member of the general partner of VVC V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The securities are held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). The Reporting Person is a director of the ultimate general partner of VVC V (Canada), but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). The Reporting Person is a managing member of the general partner of VOAF I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). The Reporting Person is a managing member of the general partner of VAF V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The securities are held by Versant Vantage I, L.P. ("VV I"). The Reporting Person is a managing member of the ultimate general partner of VV I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities were purchased by VV I.
These securities were purchased by VVC VI.